Ovid Therapeutics
NEWS
BioSpace’s Pharm Country Hotbed ranges from Connecticut, New York, New Jersey, Pennsylvania and Rhode Island.
This week’s announcement includes a step to the side for CMO Amit Rakhit, who will transition to the biotech’s advisory board.
Takeda will develop soticlestat, a first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H), as a potential treatment for developmental and epileptic encephalopathies.
It was a moderately busy week for clinical trial news, with some important reports coming out about COVID-19 vaccines. Here’s a look.
As August wraps up, there were still clinical trial announcements, although fewer than earlier this summer. Here’s a look.
Takeda Pharmaceutical and Ovid Therapeutics announced on Tuesday that they have gathered positive data from their Phase II ELEKTRA study of soticlestat in children with Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS).
Angelman Syndrome is a genetic disorder that mostly affects the nervous system.
This Clinical Catch-Up has been split into three sections: COVID-19-Related Clinical Trials; Non-COVID-19-Related Clinical Trials; and Trials Affected by the COVID-19 Pandemic. Here’s a look.
As the biopharma industry responds to the COVID-19 pandemic, some of the area’s companies are at the very frontlines of drug development against the disease, while others play supporting roles for the entire industry. Here’s a look.
JOBS
IN THE PRESS